The European Respiratory Society (ERS) 2026 Annual Congress was held September 5-9 in Barcelona, Spain. As one of the most important international academic meetings in respiratory medicine, this year’s congress gathered advances from basic research, clinical practice, and translational medicine.
At this year’s ERS, Prof. Jieming Qu’s team had 12 studies accepted, including 3 oral presentations and 9 poster presentations. Research areas span AI and digital respiratory medicine, regenerative lung-injury therapies, bronchiectasis, severe pulmonary infections, host immunity, and pulmonary mycology.
MedJ has compiled the studies for reader’ reference.
Three Oral Presentations: Lung Function Assessment, Airway Basal Stem Cell Transplantation, and Bronchiectasis Therapy Move Into a New Phase
1. DeepSpiro: Smartphone-Based Lung Function Estimation From Forced-Exhalation Sound — A Multicenter Development and Validation Study (Late Breaking Abstract)
Author: Zhaoyang Bu
Key Findings:
The study developed DeepSpiro, a multimodal deep learning model that estimates forced vital capacity (FVC) and forced expiratory volume in 1 second (FEV1) from a single forced-exhalation sound recorded on a smartphone, combined with age, sex, height, and weight. A total of 9,720 paired “exhalation sound–lung function” recordings were collected from 4,864 participants. After quality control, the multicenter validation set contained 964 cases. The model achieved R² of 0.815 and 0.819 for FVC and FEV1, respectively, with mean absolute percentage error (MAPE) of 0.113 and 0.116. Performance was further evaluated in interstitial lung disease (ILD) and chronic obstructive pulmonary disease (COPD) subgroups.
Conclusion:
DeepSpiro shows the feasibility of estimating FVC and FEV1 from smartphone-recorded exhalation sounds, providing a new technical pathway for convenient, low-cost lung function screening tools in primary care and community settings.
1. Real-World Safety and Efficacy of Autologous Airway Basal Stem Cell Transplantation to Repair Lung Injuries
Author: Yu Zhao
Key Findings:
This real-world retrospective study included 111 patients who received autologous airway basal stem cell transplantation, including 88 with COPD, 18 with ILD, and 5 with bronchiectasis. No serious adverse events related to cell therapy were observed during follow-up. At 24 weeks post-treatment, diffusing capacity of the lungs for carbon monoxide (DLCO) increased by 1.61 mmol/min/kPa from baseline, and 54.5% of patients achieved the prespecified minimum clinically important difference (MCID). At 4 weeks, the COPD Assessment Test (CAT) score decreased by 3.70 points from baseline, with 81.8% of patients achieving the corresponding MCID. FVC and FEV1 remained generally stable throughout follow-up.
Conclusion:
In this real-world cohort, autologous airway basal stem cell transplantation showed acceptable tolerability and observed improvements in pulmonary gas exchange and quality of life, providing real-world evidence to support further clinical evaluation.
1. Inhaled Tobramycin for Eradication of Pseudomonas Aeruginosa in Bronchiectasis
Author: Jin-fu Xu
Key Findings:
This multicenter, double-blind, 2×2 factorial, placebo-controlled trial was conducted at 60 centers in China and randomized 371 adult bronchiectasis patients with recent Pseudomonas aeruginosa isolation; 358 entered the modified intent-to-treat analysis. P. aeruginosa eradication rates were 41.7% with inhaled tobramycin (TIS) alone, 33.9% with TIS plus ciprofloxacin, 19.9% with ciprofloxacin alone, and 18.9% with placebo. TIS monotherapy provided an absolute increase of 22.8 percentage points versus placebo (P=0.001). Trial-related adverse events were generally similar across groups.
Conclusion:
In bronchiectasis patients with recent P. aeruginosa isolation, 12-week inhaled tobramycin significantly improved pathogen eradication rates, regardless of whether combined with a short course of oral ciprofloxacin.
Nine Posters: Bridging Basic and Clinical Research
1. A Single-Cell Atlas of the Systemic Immune Landscape in Severe Bacterial Pneumonia
Author: Yanan Li
Key Findings:
The study performed single-cell RNA sequencing and immune repertoire analysis on 40 patients with severe bacterial pneumonia and 32 healthy controls. Compared with survivors, non-survivors exhibited broader immune dysfunction, including impaired intercellular communication, blocked monocyte maturation, reduced effector T-cell function, and enhanced immunosuppressive activity of regulatory T cells (Tregs).
Conclusion:
The study characterized systemic immune features associated with different clinical outcomes of severe bacterial pneumonia, providing leads for further exploration of immune regulatory targets linked to disease progression.
1. A Multicentre Randomised Controlled Trial of Artificial Intelligence Assisted Real-Time Monitoring System for Bronchoscopy
Author: Guoliang Zhang
Key Findings:
The study enrolled 268 subjects across 3 hospitals. The AI-assisted group achieved an average coverage of 91.60% of bronchial anatomic sites, higher than 82.52% in the control group. The system identified 31 bronchial anatomic sites with mean sensitivity of 95.99% and specificity of 94.36%.
Conclusion:
The AI real-time monitoring system improved anatomic-site coverage during bronchoscopy and may serve as an adjunct tool for procedure standardization and quality control.
1. AI-Powered Cough Analysis for Community-Based COPD Screening: Deployment and Outcomes From 246 Communities Across 32 Chinese Cities (Late Breaking Abstract)
Author: Jiaxuan Mao
Key Findings:
From February to May 2026, the CoughSearch system screened 16,760 residents across 246 communities in 32 Chinese cities, with 25.1% identified as high risk for COPD. At two completed follow-up sites, 71 of 93 high-risk referrals were confirmed as COPD by spirometry, yielding a positive predictive value of 76.3%. Average screening time per person was approximately 2 minutes.
Conclusion:
The study provides preliminary support for embedding AI cough analysis into existing community health service workflows, offering a new application pathway for large-scale early COPD case finding.
1. Early-Life Susceptibility to Streptococcus Pneumoniae Is Driven by Mincle+ MDSC-Mediated Immune Suppression
Author: Wan-mei Song
Key Findings:
The study found that children have higher abundance of immunosuppressive myeloid-derived suppressor cells (MDSCs) than adults. Mechanistic studies showed that the pneumococcal capsular polysaccharide CPS-19F can promote MDSC expansion and immunosuppressive function through Mincle, involving the Syk/PI3K/Akt/iNOS signaling axis. Experimental inhibition of this pathway improved infection outcomes.
Conclusion:
MDSC-mediated immune suppression may contribute to elevated early-life susceptibility to S. pneumoniae, with the CPS/Mincle/Syk axis providing a mechanistic basis for further exploration of potential intervention strategies.
1. Mechanism of S100A4 on Enhancing the Immune-Suppressive Function of MDSCs in Pseudomonas Aeruginosa Lung Infection
Author: Yingqi Lyu
Key Findings:
Following P. aeruginosa lung infection, S100A4 levels were elevated in lung tissue, and MDSCs expressed and secreted S100A4. Further studies showed that S100A4 enhances MDSC immunosuppressive function through RAGE-related signaling pathways, and experimental S100A4 inhibition improved infection outcomes.
Conclusion:
S100A4 may be involved in immune dysregulation associated with P. aeruginosa infection and represents a potential target for host immune regulation research.
1. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Inhibit Biofilm Formation in Drug-Resistant Pseudomonas Aeruginosa Pneumonia via Glutathione Metabolism
Author: Mengmeng Shi
Key Findings:
Based on 30 P. aeruginosa clinical isolates and in vitro and in vivo experiments, the study found that MSC-derived extracellular vesicles (MSC-EVs) reduced bacterial biofilm thickness and extracellular matrix polysaccharide levels. After nebulization, MSC-EVs predominantly localized to alveolar macrophages and were associated with macrophage glutathione metabolism activation, as well as antibacterial and anti-inflammatory effects.
Conclusion:
MSC-EVs showed inhibitory effects on P. aeruginosa biofilm formation, providing preclinical evidence for non-antibiotic intervention strategies against drug-resistant pulmonary infections.
1. Asymptomatic Spread and Environmental Drivers of Pulmonary Cryptococcosis in China: A Multicentre Study
Author: Zhengtu Li
Key Findings:
This prospective study at 60 Chinese centers included 1,271 HIV-negative patients with pulmonary cryptococcosis, of whom 89.9% were non-immunocompromised. Compared with historical data, the proportion of asymptomatic patients increased from 25.2% to 41.4%. Further geospatial analysis showed that moderate vegetation coverage and PM2.5 exposure were both associated with elevated pulmonary cryptococcosis risk.
Conclusion:
The study reveals an epidemiologic trend of increased asymptomatic presentation in pulmonary cryptococcosis in China, and suggests environmental exposure factors may be associated with disease risk.
1. Targeting the RSV-CDH16 Interface: De Novo Design of Next-Generation Entry Inhibitors Against Respiratory Syncytial Virus
Author: Wenwen Zhao
Key Findings:
Through genome-wide CRISPR-Cas9 knockout screening, the study identified the role of CDH16 in RSV entry, and resolved the RSV-CDH16 interaction interface using high-resolution structural analysis. Candidate blocking peptides designed on this basis showed neutralizing activity in vitro and reduced viral replication in a mouse model.
Conclusion:
The study suggests CDH16 may be an important host factor for RSV entry, and targeting the RSV-CDH16 interface provides preclinical proof-of-concept for novel viral entry inhibition strategies.
1. Model for Early Differential Diagnosis of Disseminated Cryptococcosis and Pulmonary Cryptococcosis in HIV-Negative Patients
Author: Zhengtu Li
Key Findings:
The study included 1,691 HIV-negative patients with cryptococcosis, including 139 with disseminated cryptococcosis and 1,552 with pulmonary cryptococcosis. The predictive model achieved AUCs of 0.922 and 0.945 in the training and validation sets, respectively. Headache, positive pus smear or culture, and elevated white blood cell count were associated with increased disseminated-disease risk.
Conclusion:
The model showed strong discriminative performance in both training and validation sets, providing a potential adjunct tool for early risk identification and clinical stratification in HIV-negative cryptococcosis patients.
Summary
From smartphone exhalation-sound lung-function estimation, AI-assisted bronchoscopy, and community COPD screening, to lung-injury regenerative therapies and bronchiectasis anti-infection strategies; from severe bacterial pneumonia and P. aeruginosa host immune regulation, to RSV entry mechanisms and the epidemiology and precision diagnosis of pulmonary cryptococcosis, the 12 studies span multiple layers from mechanistic exploration and technological innovation to clinical translation.
Among them, three oral reports focused respectively on digital lung function assessment, lung-injury regenerative therapy, and bronchiectasis P. aeruginosa eradication. Nine posters extended the work into AI, severe-infection immunity, and precision diagnosis of fungal diseases, collectively presenting the team’s ongoing exploration in early identification, precise intervention, and clinical translation for respiratory diseases.